Vendor Intelligence Report: HkRoids

Executive summary

Across 55 Finnrick lab tests, HkRoids records 39 pass and 16 fail, an overall pass rate of 71%. The result is not a simple safe/unsafe verdict: the catalog is uneven. GHK-Cu and BPC-157 are the cleaner directional choices, while CJC-1295 is the obvious weak line and a vendor-forum thread discusses a Tirzepatide batch testing as a different incretin compound. Stricter grading compresses the weaker lines further.

HkRoids is also not well supported as a conventional US peptide retailer. The public record shows continuity from a 2016 raw-steroid supplier page naming a Hong Kong Shijingu entity and mainland-China contact signals into today’s peptide storefront. Current browsing found hkroids.com and its vendor forum active, but no verified US entity or address; older sister/lead domains have gone inactive, parked, or defunct.

The buyer-risk profile sits in the operating model as much as the vial tests. HkRoids uses a large WhatsApp/email sales-rep network, vendor-owned forum reputation surfaces, crypto and PayPal Friends & Family-style payment rails, and has documented customs-seizure and import-screening context. Vendor-posted lab certificates are useful only when the exact batch and vial can be matched; the report explains where that control breaks down.

For buyers already considering HkRoids, the useful conclusion is product-specific: the better-tested lines still share the same payment, labeling, and import exposure, while weaker lines should require current independent batch evidence or a different vendor.

Inside the full report:

• Per-product Finnrick pass/fail analysis and methodology-divergence charts for all 7 tested products
• Wayback timeline showing the steroid-to-peptide transition and Shijingu-linked historical records
• Domain and infrastructure review covering hkroids.com, community.hkroids.com, hkroids.net, and abandoned sister-domain leads
• Sales-representative, WhatsApp, PayPal Friends & Family, crypto, and local-bank payment-rail analysis
• Tirzepatide batch-identity incident, manual-labeling signal, and vendor-forum accountability review
• Affiliate/promotion sweep and scoped negative findings across searched X/web surfaces

Risk assessment

• Tirzepatide identity-integrity risk — high: HkRoids Tirzepatide Batch 0368 / Lot 2AZK2RJ was discussed on the vendor forum as testing as Retatrutide; Tirzepatide is 69.94% with 5 pass / 4 fail in Finnrick testing.
• CJC-1295 quality-control risk — high: CJC-1295 is the fail-heavy Finnrick line: 31.83% with 2 pass / 3 fail.
• Tesamorelin and Ipamorelin consistency risk — medium: Tesamorelin is 52.73% with 5 pass / 3 fail and Ipamorelin is 67.8% with 4 pass / 2 fail, making fresh batch verification important.
• Payment-recourse risk — high: Crypto, PayPal Friends and Family, and local bank rails leave little chargeback or refund leverage if an order fails, is seized, or is misrepresented.
• Customs and import-seizure risk — high: Forum seizure reports, misdeclaration claims, HkRoids import-screening posts, and CBP peptide enforcement make cross-border delivery and reship reliability a material concern.
• Corporate-identity and brand-verification risk — medium: No current US entity or address was verified; hkroids.com is active, but inactive/parked/defunct related domains and a large WhatsApp rep network leave buyers with weak authenticity signals.
• Quality-accountability / controlled-reputation risk — medium: The vendor-controlled forum dismissed adverse Tirzepatide testing while HkRoids also publishes selected lab certificates; buyers cannot treat the forum as independent QA.